Healthcare / BiotechnologyBSE
$398.45
-1.10 (-0.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-794.1M · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$24.4B
P/E
N/A
•EV/EBITDA
79.7x
↑ROE
-1.0%
↓Gross Margin
52.1%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.3%
FCF CAGR
—
FCF margin
-15.8%
FCF / Net income
9.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.93B · net income $-83.7M · FCF $-776.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.93B | $4.93B | $5.52B | $4.57B | $6.59B |
| Net Income | $-83.7M | $-83.7M | $-11.7M | $-332.4M | $10.78B |
| EBITDA | $297.9M | $297.9M | $408.6M | $557.3M | $16.73B |
| EPS | -1.37 | -1.37 | -0.19 | -5.43 | 176.05 |
| Gross Margin | 52.1% | 52.1% | 51.3% | 39.0% | 51.8% |
| Operating Margin | -11.3% | -11.3% | -8.0% | -23.1% | -7.9% |
| Net Margin | -1.7% | -1.7% | -0.2% | -7.3% | 163.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 |
| Cash Flow | |||||
| Free Cash Flow | $-776.7M | $-776.7M | $-794.1M | $-4.63B | $-1.21B |
| Returns | |||||
| ROE | -1.0% | -1.0% | -0.1% | -3.9% | 123.0% |
| Valuation | |||||
| P/E | — | — | — | — | 1.06 |
| EV/EBITDA | 79.68 | 79.68 | 20.94 | 12.12 | 0.67 |
| P/B | 2.92 | 2.92 | 1.05 | 0.82 | 1.30 |
| Growth & Yield | |||||
| Revenue Growth | -10.7% | -10.7% | 20.8% | -30.7% | — |
| EPS Growth | -621.1% | -621.1% | 96.5% | -103.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.19 → -1.37
Residual
-18.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.